CJC-1295 Dosage: What the Research Used and How Your Prescriber Decides

Why There Is No Standard CJC-1295 Dose

When a drug is approved, its label states a dose that was tested in trials large enough to show what works and what is safe. CJC-1295 never reached that stage. It is not approved for any use, and when it was reviewed for compounding, the FDA identified serious adverse events including increased heart rate and a systemic vasodilatory reaction, and noted that clinical data are limited. The nomination was later withdrawn.

That leaves no official reference point. The numbers that appear on websites, forums and vendor pages are not taken from a label, and most are not taken from published research either. The only published human doses come from a handful of short studies in healthy volunteers, and those studies were designed to measure hormone levels, not to find a treatment dose.

Knowing what CJC-1295 is and how it acts on the pituitary makes it easier to see why the doses in those studies cannot simply be copied. They show how the drug behaves in the body over a few weeks. They do not show what amount, if any, helps a particular person.

Doses Used in Human Studies

The main human research on CJC-1295 was two placebo controlled trials in healthy adults aged 21 to 61, lasting 28 and 49 days. In the first, volunteers received one of four ascending single doses. In the second, they received two or three doses given either weekly or every other week. After a single dose, growth hormone rose 2 to 10 fold for 6 days or more and IGF-1 rose 1.5 to 3 fold for 9 to 11 days, with larger doses producing larger rises.

The researchers reported no serious adverse reactions and concluded that 30 or 60 micrograms per kilogram were the best tolerated doses. They also saw evidence of a cumulative effect. With repeated doses, IGF-1 stayed above its starting level for up to 28 days.

A second study gave a single dose of 60 or 90 micrograms per kilogram to healthy men aged 20 to 40 and measured their growth hormone overnight a week later. Both doses raised growth hormone and IGF-1, and the researchers found no significant difference between the responses to the two doses.

Two points matter when reading these numbers. First, every dose was calculated per kilogram of body weight, so the same study dose means a different total amount for different people. Second, every participant was a healthy volunteer followed for weeks, and the outcomes were hormone levels. None of these studies tested a dose for any health goal, and none followed people for months.

How Often CJC-1295 Is Given

How far apart doses are spaced depends on how long the drug stays active. The version with DAC binds to albumin in the blood and had a measured half life of 5.8 to 8.1 days in people, which is why the studies spaced injections a week or two apart rather than daily.

Animal work shows that the interval itself changes the effect. In mice bred without the gene for GHRH, daily dosing restored normal growth while the same dose every 48 or 72 hours fell short. Results in mice do not translate directly to people, but they show why the schedule is not a detail to adjust on your own.

The cumulative effect seen in the human trials is another reason. Injecting more often than prescribed can push IGF-1 higher than intended, and higher is not automatically better. The contrast between this long acting drug and the daily schedule used for sermorelin comes down almost entirely to half life.

With DAC vs Without DAC: Why the Form Matters

Everything above applies to CJC-1295 with DAC, the form tested in published human trials. The version without DAC, often called modified GRF (1 to 29), has no albumin attachment and is cleared from the blood far faster. No published human study has established a dose or schedule for it, so the schedules for this form that circulate online, often several small injections a day, are not drawn from published trials.

The two forms are not interchangeable, and an amount that suits one says nothing about the other. Before any dose is discussed, confirm with your prescriber and pharmacy exactly which form has been prescribed and what the label says.

Combining CJC-1295 With Ipamorelin

CJC-1295 is often paired with ipamorelin, a peptide that releases growth hormone through a different receptor from the one CJC-1295 uses. In early laboratory and animal work, ipamorelin released growth hormone without raising cortisol, which is why it attracted interest as a partner peptide.

No published human trial has tested the two together, so any combined dose rests on reasoning rather than measured results. The FDA has also placed ipamorelin in its category of compounding substances that may present significant safety risks, citing a published study in which serious adverse events, including a death, occurred when ipamorelin was given intravenously. Any combination is a decision for your prescriber, who should explain that lack of evidence before suggesting one.

Human Dosing Studies at a Glance

The table below summarizes the published human studies of CJC-1295 with DAC, what participants were given and what was measured. The two Teichman trials lasted 28 and 49 days.

How a Prescriber Sets Your Dose

A licensed physician reviews your health history, current medicines and any lab work before deciding whether CJC-1295 is appropriate at all. If it is, they choose the form, the amount, the interval and how long treatment should last, and they decide how you will be monitored. Conditions affected by higher growth hormone, such as diabetes or a history of cancer, can change that decision or rule the drug out, which is why the CJC-1295 side effects and safety picture is part of every review.

Once a dose is prescribed, the volume to draw into the syringe depends on how the vial was mixed. A dosage calculator and mixing chart walks through that arithmetic, including the mix up between milligrams and micrograms that causes the most dangerous errors. Always check your numbers against the pharmacy label or with your pharmacist before the first injection.

People often want to know how far a dose will raise their hormones. Responses vary with age, sleep, body composition and other medicines, so no calculator can predict your growth hormone response, and an IGF-1 blood test is how a prescriber actually measures it.

Preparing and Injecting

CJC-1295 is usually dispensed as a freeze dried powder that is mixed with a liquid before use. Follow the pharmacy's instructions on which liquid to use, how much to add and how long the mixed vial can be kept. Mix gently rather than shaking, and do not use the solution if it looks cloudy or contains particles.

In the human studies, CJC-1295 was injected under the skin. Getting the angle, depth and site rotation right is the core of subcutaneous peptide injection technique, and your prescriber or pharmacist can walk you through it before your first dose. Rotating between sites, such as different areas of the abdomen or thigh, helps limit irritation at any one spot.

Storage, Supplies and Travel

Store CJC-1295 exactly as the pharmacy label directs, which for peptide vials typically means keeping them refrigerated and away from light. Write the mixing date on the vial so you know when it should be discarded. A package that arrives warm, or a vial left out on the counter, raises questions about CJC-1295 storage, shipping and handling that are worth putting to the pharmacy rather than guessing.

Running short of syringes or swabs partway through treatment is a common reason for missed doses, so it helps to keep a CJC-1295 supplies checklist and reorder before you run low.

If you fly within the United States, the TSA allows unused syringes when they travel with injectable medication. You must declare them at the checkpoint, and labeling your medication is recommended though not required. Time zone changes and long trips can shift a dose day, so managing peptide therapy while traveling starts with asking your prescriber how to handle a dose that falls on a travel day.

Needle Disposal

Put used needles and syringes into a sharps disposal container immediately after use. The FDA advises keeping the container out of reach of children and pets, not overfilling it, and getting rid of it according to your community's guidelines, which vary by location. Loose needles should never go into household trash or recycling, and safe disposal of needles and medical waste usually comes down to a local drop off site or a mail back program.

Monitoring and Reporting Side Effects

Because CJC-1295 raises growth hormone and IGF-1, prescribers typically monitor IGF-1 and blood sugar during treatment and adjust or stop the drug if levels move outside a safe range. Report any new or worsening symptoms to your prescriber, including a fast heartbeat, flushing, swelling, joint pain or tingling in the hands.

Serious reactions can also be reported directly to the FDA through MedWatch, its safety reporting program for patients and health professionals.

Questions to Ask Your Prescriber About Dosing

Because there is no standard dose to compare against, the conversation with your prescriber is where the real detail lives. Before you start, it helps to ask which form of CJC-1295 is being prescribed, with or without DAC, and why that form was chosen for you. Ask what the dose is in both milligrams and syringe units, so you can check it against the pharmacy label yourself.

It is also worth asking how often you will inject and what to do if a dose day is missed, so you never have to guess or double up. Ask which blood tests will be done, when they will happen and what result would lead to a lower dose or a stop. If you take other medicines, especially for diabetes, ask whether any of them change the plan.

Finally, ask how long treatment is expected to last and when it will be reviewed. Because the published research ran for weeks rather than months, a clear review point matters. Clear answers to these questions make the treatment safer and make it easier to spot a problem early.

Conclusion

CJC-1295 has no standard dose. The only published human doses, 30 to 90 micrograms per kilogram given once or repeated a week or two apart, came from short studies in healthy volunteers that measured hormone levels rather than health outcomes. They apply only to the version with DAC, and no published trial supports a combined dose with ipamorelin.

That makes dosing a medical decision: which form, how much, how often, for how long and with what monitoring. A prescriber who has reviewed your history should make it, and the pharmacy label should guide every step of mixing, storage and injection.

If you want a licensed physician to review whether CJC-1295 is appropriate for you and, if so, at what dose, start your intake.